Regulus Therapeutics Inc (RGLS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Paul C. Grint
Employees:
24
10614 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121
858-202-6300

Regulus Therapeutics, Inc. engages in the discovery and development of drugs targeting microRNAs. It is developing RG-101, which targets miR-122, a host factor for the hepatitis C virus infection. The company was founded in September 2007 and is headquartered in San Diego, CA.

Data derived from most recent annual or quarterly report
Market Cap 35.179 Million Shares Outstanding145.971 Million Avg 30-day Volume 1.044 Million
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0896 EBITDA-28.437 Million
Price to Book Value0.8835 Operating Margin0.0 Enterprise Value-6.045 Million
Current Ratio12.324 EPS Growth0 Quick Ratio11.468
1 Yr BETA 0.5396 52-week High/Low 1.05 / 0.16 Profit Margin0.0
Operating Cash Flow Growth-102.5153 Altman Z-Score-8.8731 Free Cash Flow to Firm -19.593 Million
Earnings Report2022-08-09
View SEC Filings from RGLS instead.

View recent insider trading info

Funds Holding RGLS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RGLS BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-27:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-30:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-18:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-12:
    Item 8.01: Other Events
  • 8-K: filed on 2021-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BALTIMORE DAVID

    • Director
    90,000 2022-06-09 1

    PAPADOPOULOS STELIOS

    • Director
    90,000 2022-06-09 2

    RASTETTER WILLIAM H

    • Director
    90,000 2022-06-09 1

    NUNN JASON RALEIGH

    • Director
    90,000 2022-06-09 1

    ROSEN HUGH

    • Director
    90,000 2022-06-09 1

    WITZ PASCALE

    • Director
    90,000 2022-06-09 1

    COLLIER KATHRYN J

    • Director
    90,000 2022-06-09 1

    SIMEONIDIS SIMOS

    • Director
    90,000 2022-06-09 1

    HUANG ALICE SHIH-HOU

    • Director
    90,000 2022-06-09 1

    HAGAN JOSEPH P PRESIDENT AND CEO

    • Officer
    • Director
    300,000 2022-05-10 2

    CALSADA CRISPINA CHIEF FINANCIAL OFFICER

    • Officer
    50,000 2022-05-10 2

    AKER CHRISTOPHER RAY SR. VP & GENERAL COUNSEL

    • Officer
    70,000 2022-05-10 2

    DRYGIN DENIS CHIEF SCIENTIFIC OFFICER

    • Officer
    100,000 2022-03-01 3

    MAKOWER JOSHUA

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    SANDELL SCOTT D

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    BASKETT FOREST

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    WALKER PAUL EDWARD

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    SONSINI PETER W.

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    FLORENCE ANTHONY A. JR.

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    BEHBAHANI ALI

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    MAKHZOUMI MOHAMAD

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    GROWTH EQUITY OPPORTUNITIES V, LLC

    NEW ENTERPRISE ASSOCIATES 16, L.P.

    NEA PARTNERS 16, L.P.

    NEA 16 GP, LLC

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    CHANG CARMEN

    • FORMER 10% OWNER
    No longer subject to file 2021-03-09 0

    HUANG ALICE SHIH-HOU

    BALTIMORE DAVID

    • Director
    0 2021-01-06 1

    SARISSA CAPITAL OFFSHORE MASTER FUND LP

    • 10% Owner
    0 2020-04-01 0

    SARISSA CAPITAL MASTER FUND II LP

    • 10% Owner
    76,356 2020-04-01 0

    BARRIS PETER J

    • 10% Owner
    2,052,454 2019-12-24 0

    MOTT DAVID M

    • 10% Owner
    2,052,454 2019-12-24 0

    DENNER ALEXANDER J

    SARISSA CAPITAL MANAGEMENT LP

    SARISSA CAPITAL OFFSHORE MASTER FUND LP

    SARISSA CAPITAL CATAPULT FUND LLC

    SARISSA CAPITAL HAWKEYE FUND LP

    • 10% Owner
    0 2019-12-24 0

    CHEVALLARD DANIEL R. CHIEF FINANCIAL OFFICER

    • Officer
    77,870 2019-07-01 0

    WRIGHT TIMOTHY MICHAEL CHIEF R & D OFFICER

    • Officer
    62,893 2019-02-05 0

    DEEG MARK ALBERT CHIEF MEDICAL OFFICER

    • Officer
    0 2018-05-17 0

    FOLETTA MARK G

    • Director
    81,910 2017-12-04 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    11,108,515 2017-11-17 0

    VISWANATHAN RAVI

    • 10% Owner
    10,989,010 2017-07-24 0

    SAKODA JON

    • 10% Owner
    10,989,010 2017-07-24 0

    PUTTAGUNTA CHETAN

    • 10% Owner
    10,989,010 2017-07-24 0

    GRINT PAUL C PRESIDENT & CEO

    • Officer
    • Director
    0 2017-02-15 0

    WILLIAMS DOUGLAS E

    • Director
    0 2016-06-02 0

    ALNYLAM PHARMACEUTICALS, INC.

    • 10% Owner
    No longer subject to file 2016-02-23 0

    ISIS PHARMACEUTICALS INC

    • 10% Owner
    No longer subject to file 2015-07-15 0

    CARTER BRUCE L A

    • Director
    0 2015-06-10 0

    XANTHOPOULOS KLEANTHIS G PRESIDENT AND CEO

    • Officer
    • Director
    83,921 2015-04-17 0

    GIBSON NEIL W CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2015-01-28 0

    SZEKERES DAVID LESLIE CHIEF BUSINESS OFFICER & GC

    • Officer
    0 2014-12-02 0

    ASTRAZENECA PLC

    ASTRAZENECA AB

    • 10% Owner
    4,250,000 2014-11-12 0

    ISIS PHARMACEUTICALS INC

    PARSHALL B LYNNE

    • Director
    • 10% Owner
    5,516,305 2014-11-03 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ROSEN HUGH - Director

    2022-06-10 16:16:44 -0400 2022-06-09 A 90,000 a 90,000 direct

    SIMEONIDIS SIMOS - Director

    2022-06-10 16:16:01 -0400 2022-06-09 A 90,000 a 90,000 direct

    HUANG ALICE SHIH-HOU - Director

    2022-06-10 16:19:57 -0400 2022-06-09 A 90,000 a 90,000 direct

    NUNN JASON RALEIGH - Director

    2022-06-10 16:19:15 -0400 2022-06-09 A 90,000 a 90,000 direct

    PAPADOPOULOS STELIOS - Director

    2022-06-10 16:18:30 -0400 2022-06-09 A 90,000 a 90,000 direct

    RASTETTER WILLIAM H - Director the rastetter family trust

    2022-06-10 16:17:37 -0400 2022-06-09 A 90,000 a 90,000 indirect

    WITZ PASCALE - Director

    2022-06-10 16:15:15 -0400 2022-06-09 A 90,000 a 90,000 direct

    COLLIER KATHRYN J - Director

    2022-06-10 16:24:01 -0400 2022-06-09 A 90,000 a 90,000 direct

    BALTIMORE DAVID - Director

    2022-06-10 16:21:00 -0400 2022-06-09 A 90,000 a 90,000 direct

    CALSADA CRISPINA - Officer CHIEF FINANCIAL OFFICER

    2022-05-11 16:34:36 -0400 2022-05-10 A 50,000 a 50,000 direct

    HAGAN JOSEPH P - Director - Officer PRESIDENT AND CEO

    2022-05-11 16:54:02 -0400 2022-05-10 A 300,000 a 300,000 direct

    AKER CHRISTOPHER RAY - Officer SR. VP & GENERAL COUNSEL

    2022-05-11 16:31:33 -0400 2022-05-09 A 70,000 a 70,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 22:15:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 21:45:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 21:15:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 20:45:04 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 20:15:04 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 19:45:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 19:15:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 18:45:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 18:15:04 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 17:45:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 17:15:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 16:45:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 16:15:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 15:45:04 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 15:15:03 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 14:45:04 UTC -8.8759 10.4459 2100000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 14:15:03 UTC -8.8759 10.4459 2000000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 13:45:04 UTC -6.9659 8.5359 2000000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 13:15:04 UTC -6.9659 8.5359 2000000
    REGULUS THERAPEUTICS INC RGLS 2022-06-27 12:45:03 UTC -6.9659 8.5359 2000000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin
    Squarepoint Ops LLC Regulus Therapeutics Inc 1.4% 2019-08-05 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 1.39% 2019-08-20 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 1.29% 2019-08-23 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 1.19% 2019-08-28 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 1.09% 2019-08-30 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 0.97% 2019-09-05 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 0.89% 2019-09-09 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 0.78% 2019-09-11 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 0.69% 2019-09-16 GERMANY
    Squarepoint Ops LLC Regulus Therapeutics Inc 0.58% 2019-09-19 GERMANY

    Elevate your investments